U.S. markets close in 1 hour 2 minutes
  • S&P 500

    3,926.04
    -162.81 (-3.98%)
     
  • Dow 30

    31,521.31
    -1,133.28 (-3.47%)
     
  • Nasdaq

    11,416.23
    -568.29 (-4.74%)
     
  • Russell 2000

    1,772.64
    -67.66 (-3.68%)
     
  • Crude Oil

    108.52
    -3.88 (-3.45%)
     
  • Gold

    1,816.10
    -2.80 (-0.15%)
     
  • Silver

    21.41
    -0.34 (-1.59%)
     
  • EUR/USD

    1.0479
    -0.0076 (-0.72%)
     
  • 10-Yr Bond

    2.8910
    -0.0770 (-2.59%)
     
  • GBP/USD

    1.2350
    -0.0143 (-1.14%)
     
  • USD/JPY

    128.1100
    -1.2480 (-0.96%)
     
  • BTC-USD

    29,156.47
    -608.28 (-2.04%)
     
  • CMC Crypto 200

    651.54
    -19.14 (-2.85%)
     
  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

Bristol-Myers to get negative CHMP opinion on renal cancer drugs

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, July 26 (Reuters) - Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.

The company said it was notified on Wednesday that would be receiving a negative opinion from the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency.

"We strongly disagree with this opinion. And in the interest of patients, we will pursue a reexamination," Bristol-Myers CEO Giovanni Caforio said on a conference call to discuss the company's second quarter earnings. (Reporting by Michael Erman Editing by Chizu Nomiyama)